Getting semaglutide without insurance is possible through several routes, with monthly costs ranging from under $200 for manufacturer discount programs to around $75 for compounded versions. The path you choose depends on your budget, your comfort level with compounded medications, and whether you qualify for assistance programs.
Novo Nordisk’s Direct Discount Programs
Novo Nordisk, the company that makes Wegovy and Ozempic, offers pricing specifically for people paying out of pocket through its NovoCare program. If you don’t have insurance or your plan doesn’t cover semaglutide, Wegovy injections are available for $199 per month for the first two months at the lower starter doses (0.25 mg and 0.5 mg), then $349 per month after that for all higher doses. This offer runs through March 31, 2026.
Novo Nordisk also recently released an oral version of Wegovy in pill form. For uninsured patients, the pill costs $149 per month at the starter doses through April 15, 2026, then $199 per month for the maintenance dose after that date. These prices represent a significant drop from the standard retail price, which hovers around $1,000 or more per month for both Wegovy and Ozempic.
Costco has also partnered with Novo Nordisk to offer low-dose Ozempic and Wegovy for $499 per month out of pocket, though that’s considerably more than the direct NovoCare discount pricing.
Free Medication Through Patient Assistance
If your income is low enough, you may qualify for free semaglutide through Novo Nordisk’s Patient Assistance Program. Your total household income must be at or below 400% of the federal poverty level. For a single person in 2025, that threshold is roughly $62,000 per year. The application requires proof of income and a valid prescription. You can find the current poverty level guidelines and download the application through NovoCare or the NeedyMeds website.
Telehealth Providers and Compounded Semaglutide
Telehealth platforms have become the most popular route for people paying cash. These services bundle the prescription, virtual consultation, and medication into one monthly fee, typically using compounded semaglutide rather than brand-name Wegovy or Ozempic. Compounded versions are mixed by specialty pharmacies and cost significantly less. Some providers advertise plans starting around $75 per month, with prices climbing to $149 or more at higher maintenance doses.
The process is straightforward: you fill out a health questionnaire online, a licensed provider reviews it (sometimes with a video visit, sometimes asynchronously), and the medication ships to your door. Most platforms require basic lab work before prescribing, which you can get done at a walk-in lab. A comprehensive metabolic panel typically costs $60 to $80 out of pocket depending on your state.
Safety Concerns With Compounded Versions
Compounded semaglutide is not FDA-approved, and there are real safety considerations. The FDA has flagged that some compounding pharmacies use salt forms of semaglutide, specifically semaglutide sodium and semaglutide acetate, which are chemically different from the active ingredient in Wegovy and Ozempic. The agency has stated it does not have data confirming these salt forms behave the same way in the body, and it is not aware of any lawful basis for using them in compounding.
There’s also a legal dimension. Compounding pharmacies were permitted to make semaglutide during the drug shortage, but semaglutide no longer appears on the FDA’s drug shortage list. This means the regulatory justification for compounding it has narrowed considerably, and the availability of compounded versions could change. If you go this route, look for a pharmacy that uses semaglutide base (not a salt form) and is registered as a 503B outsourcing facility, which subjects it to more FDA oversight than a traditional compounding pharmacy.
Oral Semaglutide at Retail Pharmacies
Rybelsus is the brand-name oral semaglutide tablet approved for type 2 diabetes. Its retail price without insurance is about $1,028 per month, and unlike Wegovy, it doesn’t currently have the same aggressive cash-pay discounts. The price is roughly the same whether your doctor prescribes the 3 mg, 7 mg, or 14 mg tablet. Pharmacy discount cards like GoodRx can sometimes reduce this, but the savings vary widely by location. For most uninsured patients, the NovoCare pricing on Wegovy’s new pill form at $149 to $199 per month is a far better deal than Rybelsus at full retail.
Steps to Get Started Without Insurance
- Get baseline labs. Most prescribers want a metabolic panel and sometimes thyroid or kidney function tests. You can order these yourself through direct-to-consumer lab services or walk-in clinics for $60 to $80.
- Choose your prescriber. You can see your primary care doctor, visit a weight management clinic, or use a telehealth platform. Telehealth is often the fastest and cheapest option for the visit itself.
- Decide between brand-name and compounded. Brand-name Wegovy through NovoCare runs $199 to $349 per month. Compounded semaglutide through telehealth platforms can be under $150. Weigh the cost savings against the safety and regulatory uncertainties of compounded versions.
- Check patient assistance eligibility. If your household income is under 400% of the federal poverty level, apply through NovoCare before paying out of pocket. The program can provide the medication at no cost.
- Budget for the long term. Semaglutide is typically prescribed indefinitely for weight management. Most people regain weight after stopping. Factor in the ongoing monthly expense, not just the first few months at lower starter doses.
The landscape for uninsured access to semaglutide has shifted rapidly over the past year. Novo Nordisk’s direct pricing programs have brought brand-name costs down to a range that competes more closely with compounded options, which are themselves facing increasing regulatory scrutiny. Your best starting point is checking eligibility for the patient assistance program, then comparing NovoCare pricing against telehealth compounding services based on your budget and preferences.